Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05414760
Other study ID # CLEAN
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 11, 2022
Est. completion date February 5, 2024

Study information

Verified date February 2024
Source Catharina Ziekenhuis Eindhoven
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate the formation of adhesions after third-generation endometrial ablation, with and without the intrauterine adhesion barrier.


Description:

The application of endometrial ablation (EA) has significantly increased in the past 10 years. It is an effective treatment for heavy menstrual bleeding with functional aetiology. However, the risk of post-ablative intracavitary scarring after EA is significant and can lead to long term complications, and the possible delay in diagnosing endometrial cancer. CLEAN is a prospective, multi-center, randomized, controlled, two arm pilot clinical trial. The objective is to compare the formation of adhesions after third-generation endometrial ablation, with and without the intrauterine adhesion barrier. The study will be performed on women with heavy menstrual bleeding (menorrhagia) scheduled for thermal endometrial ablation with Novasure system (Hologic) A follow-up diagnostic hysteroscopy will be performed 4-8 weeks after the ablation procedure to determine the presence and severity of IUAs according to the American Fertility Society.


Recruitment information / eligibility

Status Completed
Enrollment 1
Est. completion date February 5, 2024
Est. primary completion date February 5, 2024
Accepts healthy volunteers No
Gender Female
Age group 30 Years and older
Eligibility Inclusion Criteria: - Patient with refractory heavy menstrual bleeding scheduled for endometrial ablation with Novasure system - Women 30 years old or older; - Subjects who are willing to provide a written informed consent as approved by the applicable Ethics Committee / IRB prior to participating in this clinical investigation. - Subjects who can comply with the study follow-up and other study requirements. Exclusion Criteria: - Cavity length <4 or >8 - Perforation during ablation procedure - Previous adhesiolysis procedure or diagnosis of Asherman's disease. - Abnormal uterine cavity at the time of ablation according to ESHRE classification I to V such as unicornis, bicornis, septate, duplex - History of cervical or endometrial cancer - Active pelvic infection or history of pelvic peritonitis - Known contraindication or hypersensitivity to Womed Leaf component - Current participation in another clinical investigation that has not yet received the primary endpoint - Any other condition that makes participation in the study contrary to the patient's best interests.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Womed Leaf
Womed Leaf™ is a sterile, degradable film of poly(D,L-lactide) (PLA) and poly(ethylene oxide) (PEO). PEO is a biocompatible polymer with anti-adhesion and swelling properties. It is polymerized with hydrophobic PLA to form a degradable film. Womed Leaf™ is inserted in the uterine cavity by a gynaecologist surgeon with a 5 mm diameter flexible inserter. Once released, the film unfolds and grows into the uterine cavity to create a mechanical barrier and keep the uterine walls separated for approximately one week. It is then degraded and discharged naturally through the cervix.

Locations

Country Name City State
Netherlands Catharina Hospital Eindhoven
Netherlands St. Jans Gasthuis Weert

Sponsors (1)

Lead Sponsor Collaborator
Remko P. Bosgraaf

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy endpoint: AFS scale; a discrete number Focused on the intrauterine adhesion formation following Novasure (i.e. considering only extent of cavity involved and type of adhesions) Extent of IUA => 1 = less than 1/3 of the cavity involved and 4 = more than 2/3.
Type of IUA => 1 = filmy and 4 = dense. Sum: 1 = very light adhesions and 12 = extremely severe adhesions obstructing the whole cavity.
4-8 weeks after surgery
Primary Safety endpoint 1.1: Assessment of cavity findings Ability to perform a biopsy anywhere within the uterine cavity 4-8 weeks after surgery
Primary Safety endpoint 1.2: Assessment of cavity findings Ability to adequately visualise the endometrium to evaluate for pathologic change 4-8 weeks after surgery
Primary Safety endpoint 1.3: Assessment of cavity findings Qualitative description of the endometrial cavity (i.e. presence of viable endometrium vs cicatricial/fibrotic tissue…) 4-8 weeks after surgery
Primary Serious adverse events Number of Serious Adverse Events and Serious Device-related Adverse Events such as postablation syndrome. 3 months after surgery
Secondary Each component of AFS score at second look hysteroscopy Extent of IUA => 1 = less than 1/3 of the cavity involved and 4 = more than 2/3.
Type of IUA => 1 = filmy and 4 = dense.
4-8 weeks after surgery
Secondary Binary rate of intrauterine adhesions on hysteroscopy Yes/ No intrauterine adhesions are present 4-8 weeks after surgery
Secondary Change in menstrual bleeding Change in menstrual bleeding using Pictorial Blood Loss Assessment Chart 3 months after surgery
Secondary Level of dysmenorrhea Painful cramping associated with menstruation; 0 = no symptoms and 5 = very severe symptoms Before surgery and after 3 months
Secondary Level of patient satisfaction on ablation procedure On a scale from 0 to 5 from the worst to the best health care possible; 0 = worst health care possible and 5 = best health care possible Immediately after the surgery
Secondary Number of patients complaints Number of patient complaints (i.e. complaints related to discharge or dyspareunia) 3 months after surgery
Secondary Number of subjects for whom a second ablation is possible For each subject, the second look evaluator will assess whether it is possible to perform a second ablation if needed. 4-8 weeks after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04972032 - Efficacy of Estrogen-intrauterine Stent System After Intrauterine Adhesiolysis N/A
Recruiting NCT03381807 - Human Amniotic Epithelial Stem Cell in Treatment of Refractory Severe Intrauterine Adhesion Early Phase 1
Recruiting NCT03329898 - Comparing the Efficacy of Two Methods for the Therapy of Uterine Adhesion N/A
Completed NCT03724617 - Clinical Study of Umbilical Cord Mesenchymal Stem Cells Combined With Collagen Scaffold in the Treatment of Thin Endometrium N/A
Recruiting NCT03330873 - The Efficacy and Safety of Disposable Balloon Uterine Stent in Patients With Asherman Syndrome N/A
Completed NCT02220621 - Efficacy and Safety of Crosslinked Hyaluronan Gel for Preventing Intrauterine Adhesion N/A
Active, not recruiting NCT04963179 - PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film. N/A
Recruiting NCT03351205 - The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis N/A
Completed NCT04381728 - PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film N/A
Recruiting NCT03346317 - Comparing the Efficacy of Two Methods in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis N/A
Completed NCT04166500 - Early Outpatient Hysteroscopy Can Prevent Intrauterine Adhesion After Induced Abortion N/A
Recruiting NCT03169478 - Intrauterine Balloon Dilatation Therapy in the Prevention of Adhesion Formation After Hysteroscopic Myomectomy N/A
Recruiting NCT03171454 - Immediate and Delayed Intrauterine Balloon in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis N/A
Recruiting NCT05003869 - Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions N/A
Completed NCT02744716 - Effects of Aspirin on Uterine Endometrial Repair Severe Intrauterine Adhesion N/A
Completed NCT03131596 - Postoperative Intermittent Intrauterine Balloon Dilatation Therapy. N/A
Completed NCT04824430 - Assessment of Uterine Access, Uterine Patency and Intrauterine Adhesions Following Endometrial Ablation
Completed NCT01167296 - Safety of Leaving Cook Balloon Uterine Stent in Uterus for One Month Phase 4
Completed NCT03578172 - HMG Stimulation Versus HRT for Endometrial Preparation Prior to Blastocyst Transfer in Moderate to Severe IUA Patients N/A
Recruiting NCT04930913 - Three-dimensional Ultrasound Applying in Assessment of Intrauterine Adhesions